Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)

NCT ID: NCT02363751

Last Updated: 2021-03-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2020-08-31

Brief Summary

Open-label, non-randomized, multicenter, phase II, single arm non comparative trial evaluating toxicity and efficacy of gemcitabine plus platinum salt in combination with bevacizumab in first-line setting in metastatic collecting duct carcinoma.

Conditions

Collecting Duct Carcinoma (Kidney)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

Patients will be treated for a maximum of 6 (21 days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab)

Group Type: EXPERIMENTAL

Bevacizumab

Intervention Type: DRUG

Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).

In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up.

Interventions

Bevacizumab

Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab).

In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15 mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up.

Intervention Type: DRUG

Other Intervention Names

Avastin

Eligibility Criteria

Inclusion Criteria

1. Patients should be aged ≥18 years at the inclusion,

2. Patients with histologically confirmed metastatic collecting duct carcinoma (medullary accepted),

3. Available tumor samples for centralized reading by anatomopathologist,

4. Patients with or without nephrectomy,

5. At least one measurable lesion as per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1),

6. No prior chemotherapy nor anti-angiogenic drugs ; Prior adjuvant chemotherapy of localised disease admitted if it is stopped for more than 12 months at the inclusion date.,

7. No irradiation within 4 weeks before inclusion,

8. Absolute neutrophil counts (ANC) ≥1.5 x 10⁹/L,

9. Platelets ≥100 x 10⁹/L,

10. Hemoglobin ≥9 g/dL,

11. Hepatic function : AST and ALT ≤1.5 x ULN (≤4 x ULN in case of liver metastases); total bilirubin ≤1.5 x ULN; alkaline phosphatase <2 x ULN (≤4 x ULN in case of bone metastases),

12. Renal function : creatinine clearance ≥60 mL/min (MDRD calculation method) using cis-platin and >30 mL/min when using carboplatin,

13. Absence of proteinuria at baseline defined by <0.3 g of protein on urine sample or <0.5 g/24h on urine collection,

14. Prothrombin time (TP) or partial thromboplastin time (PTT) strictly less than 50% deviation from normal limits, of international normalized ratio (INR) strictly below 2, Note: The use of full-dose oral or parenteral anticoagulants as well as aspirin or clopidogrel is permitted as long as the INR or a PTT is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of study enrolment. Prophylactic use of anticoagulants is allowed.

15. ECG with normal or clinically insignificant as per investigator's judgement sinus rhythm,

16. ECOG Performance Status: 0 - 2,

17. Estimated life expectancy ≥12 weeks,

18. Patients who have received the information sheet, dated and signed the informed consent form,

19. Patient of child-bearing potential (for female patient: study entry after a menstrual period and a negative pregnancy test) must agree to use two medically acceptable methods of contraception (one for the patient and one for the partner) during the study and for 6 months after the last study treatment intake.

20. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,

21. Patients affiliated to the Social Security System,

Exclusion Criteria

1. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment,

2. Prior systemic treatment with chemotherapy or anti-angiogenic tyrosine kinase inhibitors such as axitinib, sunitinib, sorafenib, pazopanib, tivozanib, mTOR inhibitor (Temsirolimus or everolimus) and targeted VEGF drugs such as bevacizumab and VEGF trap,

3. Evidence of current spinal cord compression or leptomeningeal disease. Please note that patients with asymptomatic brain metastases are eligible,

4. Another histological type of renal cancer

5. Other malignancy within 3 years prior to inclusion (except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix, and/or pT1/a bladder cancer),

6. Uncontrolled hypertension (≥160 mm Hg systolic and/or ≥90 mm Hg diastolic) while receiving medication,

7. Cardio-vascular disorders: congestive heart failure ≥ NYHA II, myocardial infarction or coronary artery bypass graft in the previous six months, ongoing severe or unstable angina,

8. LVEF value strictly less than 50%,

9. Current or recent (within 2 weeks of study enrolment) initiation of aspirin, clopidogrel), oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes,

10. History of clinically significant hemorrhagic or thromboembolic events in the past six months, or known inherited predisposition to bleeding or thrombosis or History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment; History of haemoptysis ≥ grade 2 (defined as ≥2.5 mL bright red blood per episode) within 1 month of study enrolment,

11. Patients who underwent, according to the investigator, a significant surgery such as but not limited to , abdominal, thoracic or neurologic surgery within 28 days before the first treatment administration or patient with a wound that is not already healed at the first treatment administration or patients who underwent a minor surgical procedure including placement of a vascular access device, within 2 days of the first study treatment,

12. Patients with active gastro-duodenal ulcer,

13. Patients with untreated bone fracture,

14. Peripheral neuropathy grade ≥2 (Toxicity Criteria-(CTCAE) v4.0),

15. Patients with active infection requiring intravenous antibiotics at the time of first study treatment,

16. In the opinion of the investigator, any evidence of other severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease), or any other acute or chronic medical condition that would make the patient inappropriate with this study,

17. Immunocompromised patients, including known seropositivity for human immunodeficiency virus (HIV),

18. Known hypersensitivity to any component of the investigational drugs or excipients,

19. Pregnant or lactating women,

20. Person deprived of their liberty or under judicial protection (including guardianship),

21. Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule or any condition which, in the opinion of the investigator, would preclude participation in this trial. Those conditions should be discussed with the patient before registration in the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

UNICANCER

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Constance THIBAULT, Dr

Role: PRINCIPAL_INVESTIGATOR

Hôpital Européen Georges-Pompidou

Marc-Olivier TIMSIT, Dr

Role: STUDY_CHAIR

Hôpital Européen Georges-Pompidou

Locations

Institut de Cancérologie de l'Ouest-Site Paul Papin

Angers, , France

CHU Besançon

Besançon, , France

Hôpital Saint André

Bordeaux, , France

Centre François Baclesse

Caen, , France

Hôpital Henri Mondor

Créteil, , France

Centre Oscar Lambret

Lille, , France

Centre Léon Bérard

Lyon, , France

Institut Paoli-Calmettes

Marseille, , France

ICM Val d'Aurelle

Montpellier, , France

Centre Antoine Lacassagne

Nice, , France

Hôpital Saint-Louis

Paris, , France

Hôpital Européen Georges Pompidou

Paris, , France

Centre Eugène Marquis

Rennes, , France

Centre Eugene Marquis

Rennes, , France

Institut de cancérologie de l'Ouest - Site René Gauducheau

Saint-Herblain, , France

CHU Strasbourg - Hôpital Civil

Strasbourg, , France

Institut Claudius Regaud

Toulouse, , France

CHR Bretonneau

Tours, , France

Gustave Roussy, Cancer Campus, Grand Paris

Villejuif, , France

Countries

France

References

Thibault C, Flechon A, Albiges L, Joly C, Barthelemy P, Gross-Goupil M, Chevreau C, Coquan E, Rolland F, Laguerre B, Gravis G, Pecuchet N, Elaidi RT, Timsit MO, Brihoum M, Auclin E, de Reynies A, Allory Y, Oudard S. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24). Eur J Cancer. 2023 Jun;186:83-90. doi: 10.1016/j.ejca.2023.03.018. Epub 2023 Mar 23.

Reference Type: DERIVED

PMID: 37054556 (View on PubMed)

Other Identifiers

2013-001179-19

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

UC-0160/1210

Identifier Type: -

Identifier Source: org_study_id